UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
JAMA internal medicine, ISSN 2168-6106, 01/2015, Volume 175, Issue 3, pp. 401 - 407
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Alzheimer Disease - etiology | Prospective Studies | Humans | Muscarinic Antagonists - adverse effects | Male | Dementia - epidemiology | Cholinergic Antagonists - administration & dosage | Histamine H1 Antagonists - adverse effects | Muscarinic Antagonists - administration & dosage | Dementia - chemically induced | Antidepressive Agents, Tricyclic - adverse effects | Histamine H1 Antagonists - administration & dosage | Aged, 80 and over | Alzheimer Disease - epidemiology | Female | Aged | Cholinergic Antagonists - adverse effects | Antidepressive Agents, Tricyclic - administration & dosage | Cohort Studies | Medical personnel | Care and treatment | Practice | Dosage and administration | Patients | Risk factors | Parasympatholytic agents | Dementia | Index Medicus | Abridged Index Medicus
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 02/2017, Volume 2018, Issue 2, pp. CD012066 - CD012066
Pneumonia | Lungs & airways | Adrenal Cortex Hormones | Pulmonary Disease, Chronic Obstructive | Administration, Inhalation | Muscarinic Antagonists | Beta‐agonists, long‐acting, once daily | Beta‐agonists, long‐acting, twice daily | Cause of Death | Disease Progression | Randomized Controlled Trials as Topic | Forced Expiratory Volume | Steroids, inhaled | Adrenergic beta‐2 Receptor Agonists | Chronic obstructive pulmonary disease (stable) | Quality of Life | Chronic obstructive pulmonary disease, stable ‐ pharmacotherapy | Drug Therapy, Combination | Medicine General & Introductory Medical Sciences | Corticosteroids (inhaled, oral or intranasal) | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Pneumonia - etiology | Humans | Muscarinic Antagonists - adverse effects | Muscarinic Antagonists - therapeutic use | Drug Therapy, Combination - adverse effects | Adrenergic beta-2 Receptor Agonists - adverse effects | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adrenal Cortex Hormones - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Index Medicus
Journal Article
European urology, ISSN 0302-2838, 2014, Volume 67, Issue 3, pp. 577 - 588
Urology | Overactive bladder | Solifenacin | Combination therapy | Mirabegron | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Urodynamics - drug effects | Male | Muscarinic Antagonists - therapeutic use | Thiazoles - therapeutic use | Adrenergic beta-3 Receptor Agonists - adverse effects | Thiazoles - adverse effects | Urinary Bladder, Overactive - drug therapy | Urological Agents - adverse effects | Time Factors | Urinary Bladder, Overactive - physiopathology | Urination - drug effects | Acetanilides - therapeutic use | Adult | Female | Acetanilides - adverse effects | Urological Agents - therapeutic use | Urinary Bladder, Overactive - diagnosis | Double-Blind Method | Europe | Treatment Outcome | Solifenacin Succinate - therapeutic use | Adrenergic beta-3 Receptor Agonists - therapeutic use | Solifenacin Succinate - adverse effects | Urinary Bladder - physiopathology | Urinary Bladder - drug effects | Aged | Drug Combinations | Index Medicus
Journal Article
Basic & clinical pharmacology & toxicology, ISSN 1742-7835, 10/2016, Volume 119, Issue S3, pp. 75 - 85
Drugs, Investigational - adverse effects | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Muscarinic Antagonists - adverse effects | Drugs, Investigational - therapeutic use | Male | Acetylcholine Release Inhibitors - adverse effects | Muscarinic Antagonists - therapeutic use | Adrenergic beta-3 Receptor Agonists - adverse effects | Urinary Bladder - innervation | Cannabinoids - adverse effects | Purinergic P2X Receptor Antagonists - adverse effects | Urinary Bladder, Neurogenic - physiopathology | Urinary Bladder, Overactive - drug therapy | Urinary Bladder, Overactive - physiopathology | Female | Phosphodiesterase 5 Inhibitors - therapeutic use | Neurons, Efferent - metabolism | Purinergic P2X Receptor Antagonists - therapeutic use | Neurons, Afferent - drug effects | Neurons, Efferent - drug effects | Urinary Bladder, Neurogenic - drug therapy | Cannabinoids - therapeutic use | Adrenergic beta-3 Receptor Agonists - therapeutic use | Animals | Acetylcholine Release Inhibitors - therapeutic use | Urinary Bladder - physiopathology | Urinary Bladder - drug effects | Neurons, Afferent - metabolism | Drug approval | Bladder | Index Medicus
Journal Article
Dermatitis, ISSN 1710-3568, 11/2016, Volume 27, Issue 6, pp. 333 - 347
Life Sciences & Biomedicine | Dermatology | Science & Technology | Administration, Ophthalmic | Lubricant Eye Drops - adverse effects | Humans | Muscarinic Antagonists - adverse effects | Anti-Infective Agents, Local - adverse effects | Ophthalmic Solutions - adverse effects | Glaucoma - drug therapy | Adrenergic alpha-1 Receptor Agonists - adverse effects | Histamine Antagonists - adverse effects | Facial Dermatoses - etiology | Anti-Inflammatory Agents - adverse effects | Dermatitis, Allergic Contact - etiology | Prostaglandins, Synthetic - adverse effects | Antineoplastic Agents - adverse effects | Muscarinic Agonists - adverse effects | Antiviral Agents - adverse effects | Adrenergic beta-Antagonists - adverse effects | Anti-Bacterial Agents - adverse effects | Carbonic Anhydrase Inhibitors - adverse effects | Cholinergic Antagonists - adverse effects | Index Medicus
Journal Article
Respiratory medicine, ISSN 0954-6111, 2015, Volume 109, Issue 9, pp. 1155 - 1163
Pulmonary/Respiratory | Bronchodilation | Long-acting muscarinic antagonist | Long-acting beta2 agonist | Inhaled corticosteroid | Long-acting beta | agonist | Cardiac & Cardiovascular Systems | Respiratory System | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Glucocorticoids - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Benzyl Alcohols - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Muscarinic Antagonists - therapeutic use | Benzyl Alcohols - therapeutic use | Quinuclidines - administration & dosage | Dose-Response Relationship, Drug | Vital Capacity - drug effects | Quinuclidines - therapeutic use | Adrenergic beta-2 Receptor Agonists - adverse effects | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Drug Therapy, Combination | Glucocorticoids - adverse effects | Quinuclidines - adverse effects | Double-Blind Method | Muscarinic Antagonists - administration & dosage | Chlorobenzenes - adverse effects | Chlorobenzenes - therapeutic use | Quality of Life | Aged | Androstadienes - therapeutic use | Androstadienes - adverse effects | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Clinical trials | Consulting services | Lung diseases | Steroids | Studies | Chronic obstructive pulmonary disease | Drug dosages | Respiratory diseases | Mortality | Index Medicus
Journal Article
European urology, ISSN 0302-2838, 2013, Volume 64, Issue 6, pp. 1003 - 1012
Urology | Storage symptoms | Voiding symptoms | Solifenacin | Tamsulosin OCAS | Lower urinary tract symptoms | no | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Urinary tract. Prostate gland | Nephrology. Urinary tract diseases | Biological and medical sciences | Medical sciences | Urinary system involvement in other diseases. Miscellaneous | Tablets | Humans | Muscarinic Antagonists - adverse effects | Solifenacin Succinate | Male | Quinuclidines - administration & dosage | Adrenergic alpha-1 Receptor Antagonists - administration & dosage | Absorption | Lower Urinary Tract Symptoms - drug therapy | Adrenergic alpha-1 Receptor Antagonists - adverse effects | Muscarinic Antagonists - pharmacokinetics | Quinuclidines - adverse effects | Double-Blind Method | Administration, Oral | Adrenergic alpha-1 Receptor Antagonists - pharmacokinetics | Tetrahydroisoquinolines - administration & dosage | Tetrahydroisoquinolines - adverse effects | Sulfonamides - pharmacokinetics | Muscarinic Antagonists - administration & dosage | Tetrahydroisoquinolines - pharmacokinetics | Sulfonamides - adverse effects | Aged | Drug Combinations | Sulfonamides - administration & dosage | Quinuclidines - pharmacokinetics | Tamsulosin hydrochloride | Index Medicus
Journal Article
European urology, ISSN 0302-2838, 2013, Volume 64, Issue 2, pp. 228 - 243
Urology | Muscarinic antagonists | Prostatic hyperplasia | 5α-reductase inhibitors | Lower urinary tract symptoms | Adrenergic α1-receptor antagonists | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Tumors of the urinary system | Urinary tract. Prostate gland | Nephrology. Urinary tract diseases | Biological and medical sciences | Medical sciences | Urinary system involvement in other diseases. Miscellaneous | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Muscarinic Antagonists - adverse effects | Lower Urinary Tract Symptoms - physiopathology | Male | Treatment Outcome | 5-alpha Reductase Inhibitors - therapeutic use | Muscarinic Antagonists - therapeutic use | Evidence-Based Medicine | Prostatic Hyperplasia - diagnosis | Lower Urinary Tract Symptoms - drug therapy | Time Factors | Adrenergic alpha-1 Receptor Antagonists - therapeutic use | 5-alpha Reductase Inhibitors - adverse effects | Lower Urinary Tract Symptoms - diagnosis | Adrenergic alpha-1 Receptor Antagonists - adverse effects | Phosphodiesterase 5 Inhibitors - therapeutic use | Prostatic Hyperplasia - physiopathology | Drug Therapy, Combination | Prostatic Hyperplasia - drug therapy | Drugs | Medical colleges | Hospitals | Drug therapy, Combination | Drug approval | Index Medicus
Journal Article